Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments

J Thorac Oncol. 2019 Nov;14(11):1881-1883. doi: 10.1016/j.jtho.2019.08.005.

¹ Department of Medical Oncology, Catalan Institute of Oncology, Clinical Research in Solid Tumors (CReST) Group, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain. Electronic address: esnadal@iconcologia.net.
² Department of Medical Oncology, Catalan Institute of Oncology, Clinical Research in Solid Tumors (CReST) Group, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain.
³ Cell Death Regulation Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.

No abstract available

Publication types